leisure time -WSS

leisure time

author：fashion 2025-09-27 12:55:39 - browse：8

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series A round in the industry this year.

ReNAgade launched in May with hopes of becoming a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. These types of medicines are in high demand following the advent of mRNA vaccines for Covid and RNA-silencing therapies made by companies like Alnylam Pharmaceuticals.

ReNAgade was able to capitalize on that excitement when it raised a $300 million Series A round led by MPM Capital’s BioImpact Capital and F2 Ventures. But in recent days, the company decided to lay off around 10% of its 100-person team, according to a company statement and former employees’ posts on social media.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Drug for rare kidney disease narrowly misses mark in clinical trial

explore

entertainment

WSS

Artificial intelligence use in health care faces greater scrutiny in 2024

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Second xenotransplant done with gene

Abbott's new heart device gets FDA advisory panel nod

Long Covid research funding gets a major boost from NIH

Study gives hint on South Asians’ higher risk of cardiovascular disease

focus

leisure time

leisure time

Tori Bowie and the unacceptable rates of Black maternal death

Hearing on Medicare drug price negotiation gets unusually heated

DIEP, the 'gold standard' of breast reconstruction, is under threat

Long Covid research funding gets a major boost from NIH

The high cost of giving birth even with insurance

Latigo launches with $135 million for Vertex

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Heart attack and stroke risk calculators need revising

EpiPen alternative approval delay highlights citizen petition issue

knowledge

STAT Virtual Event: Putting AI to the Test

Senators: Long

Lasker Awards 2023: Winners in biomedical research

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Long Covid research funding gets a major boost from NIH

ACIP vaccine advisory panel sees its vacancies filled

explore

entertainment

focus

leisure time